West Point
-
Merck’s Montco Tax Challenge Sparks Concern Over School Funding
Merck’s massive presence in Upper Gwynedd has long made the pharmaceutical giant one of Montgomery County’s most influential employers and taxpayers. Now, a new tax assessment appeal tied to the company’s local campuses could have major financial implications for the community, writes Dan Sokil for The Repoter. Merck is seeking new assessments for two large…
-
Merck Leads the Pharmaceutical Pack with Net-Zero Strategy
Pharmaceutical giant Merck is accelerating its push toward net-zero emissions, renewable energy and long-term environmental stewardship, writes Chloe Williment for Sustainability Magazine. Merck has committed to reducing energy demand while rapidly expanding its use of renewable power, particularly across energy-intensive healthcare manufacturing. Over the past five years, the company has secured 209 megawatts of renewable…
-
Merck Invests $9.2B in Cidara to Boost Breakthrough Flu Drug
Merck is expanding its respiratory-health portfolio, the company announced in a press release. The pharmaceutical giant with significant operations throughout Montco announced a $9.2 billion agreement to acquire Cidara Therapeutics. The deal centers on CD388, a long-acting antiviral designed to prevent influenza in adults who face higher risks of complications. CD388 is currently in a…
-
Merck Doubles Down on Domestic Manufacturing with $70 Billion Investment
Pharmaceutical giant Merck is boosting its U.S. investments to more than $70 billion, according to Reuters. The move underscores its commitment to strengthening domestic manufacturing and research. The company already has major operations throughout Montco. It plans to expand biologics and small-molecule production and enhance R&D capabilities across its U.S. network. Merck’s expansion includes construction…
-
Merck’s Oral Cholesterol Therapy Offers Easier Alternative to Injections
Merck, the pharmaceutical giant with multiple locations across Montco, is reporting success with a new oral cholesterol drug, according to Reuters. The drug, enlicitide decanoate, recently met its main goal in a late-stage trial by reducing LDL (bad cholesterol) levels, which is a major risk factor for heart disease. Merck anticipates patent losses for their…
-
GSK Partners with Chinese Pharma Co. in $500M Deal
Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based Hengrui Pharma, writes the company in a press release. The $500 million collaboration unlocks the potential for up to 12 new treatments, bolstering GSK’s pipeline well beyond 2031. The partnership will put a strong focus on respiratory diseases,…
-
Merck’s West Point Presence Remains Strong Amid Riverside Closure
As Merck moves forward with plans to close their Riverside facility, the company remains committed to its West Point location and other sites, writes Nathan Owens for Manufacturing Drive. The Riverside plant, which once employed 300 people, was originally slated to cease production in 2024. Merck hasn’t disclosed why the timeline was delayed but noted…
-
J&J Vaccine, Once Produced in Montco’s West Point, Drops in Popularity
Johnson & Johnson’s vaccine, popular for its one-shot dose, is losing its steam. J&J is now scaling back production of the vaccine, writes Jared S. Hopkins and Peter Loftus for The Wall Street Journal. The pharmaceutical giant paired up with its competitor Merck, after the Rahway, N.J.-based company was unsuccessful in its efforts to produce its…
-
West Point-, Lansdale-Homed Merck Formalizes Purchase of Silicon Valley Biosciences Company
Merck — the North Jersey-centric big pharma firm with significant Montco outposts in West Point and Lansdale — has entered into a purchase agreement to acquire Imago Biosciences of Redwood City, Calif., southwest of San Francisco. John George provided the details of the intended $1.35 billion transaction in the Philadelphia Business Journal. The acquisition is…
-
Despite US Competition, Merck’s COVID-19 At-home Treatment Going Strong in Other Countries
While the experimental COVID-19 pill developed by Merck, the pharmaceutical giant with sizable operations in West Point, is being edged out by Pfizer’s antiviral pill nationally, it is still the top at-home treatment in other countries, such as Japan, writes Jared S. Hopkins for The Wall Street Journal. Pfizer’s antiviral drug, Paxlovid, totaled more than…
-
Merck’s Experimental COVID-19 Pill is Less Effective Than Predicted by Early Clinical Trials
The experimental COVID-19 pill developed by Merck, the pharmaceutical giant with sizable operations in West Point, and its partner Ridgeback Biotherapeutics, is less effective than had been predicted by early clinical trials, writes Katie Shepherd for The Washington Post. According to the data released by the two companies in October, Molnupiravir had shown promise in…
-
Merck Drug One Step Closer to Becoming First At-Home COVID-19 Treatment
A COVID-19 pill created by Merck, the pharmaceutical giant with sizable operations in West Point, and Ridgeback Biotherapeutics performed well in a key study and is one step closer to becoming the first, easy-to-use, at-home treatment for the deadly virus, write Jared S. Hopkins and Betsy McKay for The Wall Street Journal. According to the…
-
Merck Acquiring Acceleron Pharma for Around $11.5B
Merck, the pharmaceutical giant with sizable operations in West Point, is acquiring Acceleron Pharma for around $11.5 billion, according to a staff report from CNBC. The move is broadening Merck’s portfolio beyond the cancer drug Keytruda with potential treatments that could mean fresh revenue for the company. Merck is gaining access to sotatercept, Acceleron’s rare…
-
Merck CEO Shares Best Practices for Improving D&I Within Workplace
Kenneth Frazier, CEO of Merck, the pharmaceutical giant with sizable operations in West Point, shared best practices on how to improve diversity, equity, and inclusion within a workplace during a recent morning panel at the B.PHL Innovation Fest, writes Kennedy Rose for the Philadelphia Business Journal. The key part of the work to make internal…
-
West Point-based Merck’s Corporate Philanthropy Helped Save Millions from River Blindness
Through its corporate philanthropy, Merck, the pharmaceutical giant with sizable operations in West Point, helped save millions of people throughout the world from River Blindness, writes Justus R. Hope for The Desert Review. Dr. Roy Vagelos, who led Merck in the 1980s, discovered that millions of the poorest Africans were being blinded by a parasite. He knew…
-
Chief Executive Magazine Names Merck’s Kenneth Frazier CEO of the Year
Kenneth Frazier, CEO of Merck, the pharmaceutical giant with sizable operations in West Point, has been named CEO of the Year by Chief Executive magazine, writes Alex Keown for BioSpace. Upper Gwynedd-based Frazier, who will retire from his role at the end of next month, was selected by an independent committee for the prestigious title.…
-
Merck’s Cancer Antibody Granted Another Approval by FDA
Merck, the pharmaceutical giant with sizable operations in West Point, has received another approval for its blockbuster cancer antibody Keytruda, writes Mark Terry for BioSpace. The Food and Drug Administration approved the checkpoint inhibitor combined with Genentech’s Herceptin and fluoropyrimidine-containing and platinum-containing chemotherapy for the first-line treatment of advanced gastric cancer. The drug was approved…
-
Merck CEO Urges Corporations to Take a Stand for Democracy
Kenneth Frazier, Merck CEO, the pharmaceutical giant with sizable operations in West Point, has been at the forefront of efforts to mobilize hundreds of major corporations and business executives to publicly take a stand against restrictions on voting rights, writes Catherine Dunn for The Philadelphia Inquirer. He expanded on this message while he was delivering…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
